1. Market Research
  2. > Pharmaceutical
  3. > OTC Market Trends
  4. > Rx-OTC Switch Opportunities : Trends in OTC, category analysis, case studies and future opportunities

Summary
After years of buoyant growth, the pharmaceutical industry is facing up to a more challenging time. With the growing cost of developing novel drugs, combined with rising regulatory pressures, the use of lifecycle management is playing an ever-more important role in the increasingly cost-conscious pharma industry. This report identifies actual opportunities in OTC switching.

Key Findings
- The pharmaceutical market is changing. Since 2007, sales of OTC drugs have outstripped those for their prescription counterparts. Whereas once consumer health products were seen as a lucrative sideline, they are becoming a major focus for pharmaceutical companies. Between 2008 and 2013, worldwide OTC growth averaged 6.5% compared to 4.5% for Rx.

- Creating new categories can be fraught with risk. This was shown by the attempts of GSK to introduce the weight-loss therapy area with its Alli (orlistat 60mg capsules). After a promising start, sales collapsed due to concerns over both efficacy and safety.

- With a large and rapidly expanding population, Indonesia is catching the eye of Western multinationals in a number of industries. Within the pharma industry, self-medication is well established and these drugs account for 40% of drug spending.

Synopsis
This report takes an in-depth look at the market for Rx-OTC switches. It considers which categories have the most potential for switching, analyzing both past performance and expected future outcomes, and then examines specific candidates.

Reasons To Buy
- Identify products that have the most Rx-OTC switching potential.

- Analyze the product categories that are changing the Rx-OTC environment.

- Understand why some key Rx-OTC switches have failed.

- Use case studies to assess the revenues generated by successful switches.

Table Of Contents

Rx-OTC Switch Opportunities : Trends in OTC, category analysis, case studies and future opportunities

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Over-the-Counter (OTC) Drugs and Dietary Supplements: Global Markets

Over-the-Counter (OTC) Drugs and Dietary Supplements: Global Markets

  • $ 6650
  • Industry report
  • March 2017
  • by BCC Research

Use this report to: - Receive information concerning the dynamics and forecasts in the OTC drugs and dietary supplements market - Receive information pertaining to the major regional trends in the global ...

U.S. Insomnia Market by Non-Pharmacological Therapy, Prescription Sleep Aids, Orexin Antagonist & OTC Treatment - Forecasts to 2021

U.S. Insomnia Market by Non-Pharmacological Therapy, Prescription Sleep Aids, Orexin Antagonist & OTC Treatment - Forecasts to 2021

  • $ 5650
  • Industry report
  • January 2017
  • by MarketsandMarkets

The U.S. insomnia market is projected to reach USD 4.24 billion by 2021 from USD 3.38 billion in 2016, growing at a CAGR of 4.6% from 2016 to 2021 In 2016, the cognitive behavioural therapy for insomnia ...

Global OTC Analgesics Market - Growth, Trends and Forecast (2017 - 2022)

Global OTC Analgesics Market - Growth, Trends and Forecast (2017 - 2022)

  • $ 4250
  • Industry report
  • February 2017
  • by Mordor Intelligence LLP

The global OTC Analgesics market accounted for a market value of USD XX billion in 2015. The market is expected to reach USD XX billion in 2016 and USD XX billion by 2021, growing at a CAGR of xx% during ...

Otc Drugs Markets In China

January 2017 $ 4000

Otc Drugs Companies In China

January 2017 $ 1800

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.